Search results for: NICE
Filter search results
OHE at ISPOR Europe: Presentations
19 November 2014
…Assessment for NICE: How to Do the Calculations. Discussion Leaders: Jeanette Kusel (Costello Medical Consulting Ltd), Meindert Boysen (NICE), Koonal K. Shah (OHE) and Anthony J Hatswell (BresMed). Ispor workshop…
New OHE Research Paper: Uncertainty and Risk in HTA Decision Making
7 December 2016
…Institute for Health and Care Excellence (NICE). Uncertainty has a number of definitions, and components, which are explored. The first interpretation derives from risk aversion. We explore several factors that…
How Important are the Differences Between the EQ-5D-5L and EQ-5D-3L Value Sets?
24 March 2017
…which has been used for two decades, e.g. in evidence submitted to NICE (Dolan, 1997); – a ‘crosswalk’ value set (van Hout et al., 2012), which maps patients’ EQ-5D-5L data…
Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
18 December 2017
…of health technology assessment (HTA) evaluations conducted in the UK by NICE, AWMSG and SMC: OHE’s Medicines Tracker. We considered centrally authorised products (CAP) approved between 1 January 2011 and…
Appraising Ultra-Orphan Drugs: Is Cost-per-QALY Appropriate?
22 March 2018
…gained decision rule to appraise treatments for very rare conditions, as part of the NICE Highly Specialised Technologies (HSTs) programme. The NICE HST programme started in 2013 and its interim…
Generating Preference-based Values for the EQ-5D-Y to Support Its Use in HTA
31 January 2019
OHE’s Koonal Shah and Oliver Rivero-Arias presented at a NICE Technical Forum on the topic of valuing health in children and adolescents. OHE’s Koonal Shah and Oliver Rivero-Arias recently presented…
Valuing Health at the End of Life: A Stated Preference Discrete Choice Experiment
1 December 2012
In 2009, the UK’s National Institute for Health and Clinical Excellence (NICE) issued supplementary advice that its Appraisal Committees are to consider when assessing treatments that extend life at the…
Koonal Shah
31 July 2019
Koonal Shah is an associate director and head of science policy at NICE. His project portfolio includes overseeing the NICE Listens deliberative public engagement programme, directing the process for making…
Recent Statistics on Orphan Approvals in Scotland and England
23 August 2011
…5 Average across indications 29 43 Minimum 1 2 50 percentile 12 25 Maximum 179 179 NICE Decisions on OMPs[*] NICE has assessed nine indications for orphan conditions: azacitidine for…